Molina Healthcare (NYSE:MOH) Releases Earnings Results, Beats Estimates By $0.78 EPS

Molina Healthcare (NYSE:MOH) posted its earnings results on Wednesday. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.78, FiscalAI reports. The company had revenue of $10.80 billion during the quarter, compared to analysts’ expectations of $10.91 billion. Molina Healthcare had a net margin of 0.42% and a return on equity of 8.65%. Molina Healthcare’s quarterly revenue was down 3.1% on a year-over-year basis. During the same period last year, the company posted $6.08 earnings per share. Molina Healthcare updated its FY 2026 guidance to 5.000- EPS.

Molina Healthcare Stock Up 13.8%

Shares of MOH opened at $174.16 on Friday. The firm has a market capitalization of $9.07 billion, a P/E ratio of 51.53 and a beta of 0.55. Molina Healthcare has a 12-month low of $121.06 and a 12-month high of $333.22. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.97. The firm has a fifty day moving average price of $145.10 and a 200-day moving average price of $159.45.

Key Stories Impacting Molina Healthcare

Here are the key news stories impacting Molina Healthcare this week:

• Positive Sentiment: Beat on earnings and favorable medical-cost trends: MOH reported quarterly EPS above consensus ($2.35 vs. ~$2.16) and cited controlled medical costs that supported adjusted profit. Molina (MOH) Q1 Earnings Surpass Estimates
• Positive Sentiment: Company reaffirmed FY‑2026 EPS guidance, providing a roadmap for the year and giving investors more certainty on outlook despite near‑term volatility. Molina Healthcare soars 15% after beating Q1 earnings, reaffirms FY26 guidance
• Positive Sentiment: Market reaction highlighted that lower-than‑expected medical costs and favorable cost control helped results and after‑hours trading. Molina Healthcare beats quarterly profit estimates on controlled medical costs
• Neutral Sentiment: Top‑line roughly in line/slightly below expectations: revenue was about $10.8B (down ~3% year‑over‑year) and described by some outlets as in line with estimates, limiting upside from the sales side. Molina Healthcare (NYSE:MOH) posts Q1 CY2026 sales in line with estimates
• Neutral Sentiment: Earnings call and full transcript released — useful for hearing management commentary on membership trends, pricing and Medicare rate impact (read the details if you trade the name). Molina Healthcare, Inc. (MOH) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Significant year‑over‑year profit decline and membership pressure: reported EPS and net income are far below last year’s levels (prior year benefited from exceptional items), and management flagged shrinking membership and lower premiums — risks to near‑term revenue and margins. MOH Q1 EPS Tops Estimates on Lower Medical Costs, Membership Declines
• Negative Sentiment: Guidance vs. consensus: management’s FY‑2026 EPS framework (~5.00) is roughly in line but slightly below some Street models (~5.04 consensus), which could cap upside if execution slips. Molina Healthcare earnings report and guidance

Wall Street Analyst Weigh In

A number of analysts have issued reports on MOH shares. Barclays reduced their price objective on Molina Healthcare from $164.00 to $133.00 and set an “underweight” rating on the stock in a research note on Tuesday, February 10th. Weiss Ratings reissued a “sell (d+)” rating on shares of Molina Healthcare in a report on Tuesday. Wall Street Zen upgraded shares of Molina Healthcare from a “strong sell” rating to a “sell” rating in a research report on Sunday, April 19th. Mizuho lowered their price objective on Molina Healthcare from $220.00 to $180.00 and set an “outperform” rating for the company in a research note on Thursday, March 12th. Finally, Cantor Fitzgerald cut their target price on Molina Healthcare from $180.00 to $144.00 and set a “neutral” rating on the stock in a research report on Monday, February 9th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Molina Healthcare currently has an average rating of “Hold” and an average price target of $169.21.

Institutional Investors Weigh In On Molina Healthcare

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC grew its stake in Molina Healthcare by 217.0% in the 3rd quarter. AQR Capital Management LLC now owns 2,934,130 shares of the company’s stock worth $561,475,000 after acquiring an additional 2,008,458 shares in the last quarter. UBS Group AG increased its position in shares of Molina Healthcare by 320.7% during the third quarter. UBS Group AG now owns 603,934 shares of the company’s stock worth $115,569,000 after acquiring an additional 460,372 shares during the period. Victory Capital Management Inc. raised its stake in shares of Molina Healthcare by 46.4% during the fourth quarter. Victory Capital Management Inc. now owns 1,410,604 shares of the company’s stock valued at $244,796,000 after acquiring an additional 447,078 shares in the last quarter. Invesco Ltd. raised its stake in shares of Molina Healthcare by 24.2% during the fourth quarter. Invesco Ltd. now owns 1,690,981 shares of the company’s stock valued at $293,453,000 after acquiring an additional 329,679 shares in the last quarter. Finally, Viking Global Investors LP bought a new position in Molina Healthcare in the second quarter worth approximately $79,665,000. Institutional investors own 98.50% of the company’s stock.

About Molina Healthcare

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.